Natural product-based therapy for p53-deficient tumors: Cucurbitacin I (JSI-124) suppresses and increases the expression of DNp63α and IAPP(Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene, 7/April/2015, 13.01

Regenerative therapy for Diabetes mellitus: 5-aminoimidazole-4-carboxamide riboside (AICAR) promotes an insulin sensitized state via up regulation of reprogramming protein Lin28, 7/April/2015, 10.48 am
April 7, 2015
Small RNAs add more years into your life: MiRNA-27a inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via down regulation of its target gene, 7/April/2015, 14.47
April 7, 2015
Show all

A recent study from the [1] Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA; [2] Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA; [3] Graduate School of Biomedical Sciences, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA; and [4] Metastasis Research Center, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA shows that“IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.” This study was published in the 29 January  2015 issue of the Journal “Nature” (the no.1 journal in Science with an I.F of 42) by Prof. Flores ER, Venkatanarayan A and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for p53-deficient tumors: Cucurbitacin I (JSI-124) suppresses and increases the expression of DNp63α and IAPP(Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene.

Significance:  Cancer suppressor p53 is mutated in more than 50% of different human cancers, while its pathway is altered in about 80% of different human tumors. This study suggests a therapeutic strategy as to how p53-deficient or mutant p53 expressing human cancers can be cured by suppressing its “oncogenic version of homologous protein p63” such as DNp63α. Cucurbitacin I (JSI-124), by suppressing the expression of its target gene, it may decrease the expression of DNp63α and thereby increase the expression of IAPP(Amylin). Thus, pharmacological formulations encompassing “Cucurbitacin I (JSI-124) or its analogues” can be used to inhibit the progression of p53-deficient human tumors.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Web: http://genomediscovery.org

CitationBoominathan, Natural product-based therapy for p53-deficient tumors: Cucurbitacin I (JSI-124) suppresses and increases the expression of DNp63α and IAPP(Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene, 7/April/2015, 13.00, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Undisclosed information: How Cucurbitacin I (JSI-124) suppresses and increases the expression of DNp63α and IAPP, respectively

* Research cooperation

Comments are closed.